{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T06:18:07Z","timestamp":1787811487481,"version":"build-2784847793"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Soft tissue sarcomas (STS) are rare mesenchymal malignancies with limited treatment options in advanced stages. Anthracycline-based chemotherapy remains the standard of care but yields modest outcomes with significant toxicity, underscoring the need for more effective strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed 56 patients with advanced STS who received PD-1 inhibitor-based therapy at Tianjin Medical University Cancer Institute and Hospital between January 2021 and January 2026. Treatment regimens included immunotherapy alone or in combination with chemotherapy or targeted therapy. The observed primary endpoints were median progression-free survival (mPFS) and median overall survival (mOS). Survival outcomes were analyzed by Kaplan\u2013Meier analysis; factors associated with prognosis were identified by a Cox proportional hazards regression model. Outcomes were compared with a historical cohort of 53 patients treated with chemotherapy alone.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 56 patients were included, and the median follow-up time in the immunotherapy cohort was 19.2 months (range, 1.32\u201352.8 months). Patients with UPS had a longer median PFS than those with non-UPS histology (P\u00a0=\u00a00.045). Patients receiving immunotherapy combined with chemotherapy had longer median PFS (P\u00a0=\u00a00.047) and median OS (P\u00a0=\u00a00.046) compared with those receiving immunotherapy without chemotherapy. Multivariable Cox regression identified UPS histology (P\u00a0=\u00a00.023) and immunotherapy combined with chemotherapy (P\u00a0=\u00a00.047) as factors associated with PFS in advanced STS. Compared with 53 patients who received chemotherapy alone, the immunotherapy-based comprehensive treatment group had longer median PFS in the overall population (P\u00a0=\u00a00.023); the pure chemoimmunotherapy group (n = 22) also showed longer PFS (P\u00a0=\u00a00.014). This association was also observed in the UPS subgroup (P\u00a0=\u00a00.006). Treatment-related adverse events were predominantly grade 1\u20132; no grade 4\u20135 severe adverse events or treatment-related deaths occurred.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Immunotherapy-based regimens, particularly chemoimmunotherapy, showed a suggested PFS benefit over conventional chemotherapy in advanced STS, with UPS showing a suggested association with disease control. The safety profile was acceptable. Nevertheless, the limitations inherent to the retrospective design, historical controls, modest sample size, and immature overall survival data warrant cautious interpretation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1918276","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T05:33:40Z","timestamp":1787808820000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Immunotherapy-based salvage therapy in advanced soft tissue sarcoma after first-line chemotherapy: a retrospective single-center analysis with emphasis on undifferentiated pleomorphic sarcoma"],"prefix":"10.3389","volume":"17","author":[{"given":"Zhichao","family":"Liao","sequence":"first","affiliation":[{"name":"Department of Bone and Soft Tissue Tumors, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital","place":["Tianjin, China"]},{"name":"Tianjin\u2019s Clinical Research Center for Cancer","place":["Tianjin, China"]},{"name":"State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junbo","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Bone and Soft Tissue Tumors, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital","place":["Tianjin, China"]},{"name":"Tianjin\u2019s Clinical Research Center for Cancer","place":["Tianjin, China"]},{"name":"State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haotian","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Bone and Soft Tissue Tumors, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital","place":["Tianjin, China"]},{"name":"Tianjin\u2019s Clinical Research Center for Cancer","place":["Tianjin, China"]},{"name":"State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Bone and Soft Tissue Tumors, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital","place":["Tianjin, China"]},{"name":"Tianjin\u2019s Clinical Research Center for Cancer","place":["Tianjin, China"]},{"name":"State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Bone and Soft Tissue Tumors, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital","place":["Tianjin, China"]},{"name":"Tianjin\u2019s Clinical Research Center for Cancer","place":["Tianjin, China"]},{"name":"State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyu","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Bone and Soft Tissue Tumors, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital","place":["Tianjin, China"]},{"name":"Tianjin\u2019s Clinical Research Center for Cancer","place":["Tianjin, China"]},{"name":"State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanxin","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Bone and Soft Tissue Tumors, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital","place":["Tianjin, China"]},{"name":"Tianjin\u2019s Clinical Research Center for Cancer","place":["Tianjin, China"]},{"name":"State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sijia","family":"Ren","sequence":"additional","affiliation":[{"name":"Department of Bone and Soft Tissue Tumors, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital","place":["Tianjin, China"]},{"name":"Tianjin\u2019s Clinical Research Center for Cancer","place":["Tianjin, China"]},{"name":"State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwu","family":"Ren","sequence":"additional","affiliation":[{"name":"Department of Bone and Soft Tissue Tumors, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital","place":["Tianjin, China"]},{"name":"Tianjin\u2019s Clinical Research Center for Cancer","place":["Tianjin, China"]},{"name":"State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haixiao","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Bone and Soft Tissue Tumors, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital","place":["Tianjin, China"]},{"name":"Tianjin\u2019s Clinical Research Center for Cancer","place":["Tianjin, China"]},{"name":"State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruwei","family":"Xing","sequence":"additional","affiliation":[{"name":"Department of Bone and Soft Tissue Tumors, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital","place":["Tianjin, China"]},{"name":"Tianjin\u2019s Clinical Research Center for Cancer","place":["Tianjin, China"]},{"name":"State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Teng","sequence":"additional","affiliation":[{"name":"Department of Bone and Soft Tissue Tumors, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital","place":["Tianjin, China"]},{"name":"Tianjin\u2019s Clinical Research Center for Cancer","place":["Tianjin, China"]},{"name":"State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Bone and Soft Tissue Tumors, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital","place":["Tianjin, China"]},{"name":"Tianjin\u2019s Clinical Research Center for Cancer","place":["Tianjin, China"]},{"name":"State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanyi","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Bone and Soft Tissue Tumors, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital","place":["Tianjin, China"]},{"name":"Tianjin\u2019s Clinical Research Center for Cancer","place":["Tianjin, China"]},{"name":"State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gengpu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Bone and Soft Tissue Tumors, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital","place":["Tianjin, China"]},{"name":"Tianjin\u2019s Clinical Research Center for Cancer","place":["Tianjin, China"]},{"name":"State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Bone and Soft Tissue Tumors, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital","place":["Tianjin, China"]},{"name":"Tianjin\u2019s Clinical Research Center for Cancer","place":["Tianjin, China"]},{"name":"State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jilong","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Bone and Soft Tissue Tumors, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital","place":["Tianjin, China"]},{"name":"Tianjin\u2019s Clinical Research Center for Cancer","place":["Tianjin, China"]},{"name":"State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"70","DOI":"10.32074\/1591-951X-213","article-title":"The 2020 WHO classification of soft tissue tumours: news and perspectives","volume":"113","author":"Sbaraglia","year":"2021","journal-title":"Pathologica"},{"key":"B2","doi-asserted-by":"publisher","first-page":"iii102","DOI":"10.1093\/annonc\/mdu254","article-title":"Soft tissue and visceral sarcomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"25","year":"2014","journal-title":"Annals of Oncology"},{"key":"B3","first-page":"829","article-title":"Soft tissue sarcoma","volume-title":"Cancer Epidemiology and Prevention","author":"Berwick","year":"2017"},{"key":"B4","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1097\/SLA.0000000000000869","article-title":"Lessons learned from the study of 10,000 patients with soft tissue sarcoma","volume":"260","author":"Brennan","year":"2014","journal-title":"Annals of Surgery"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1016\/j.annonc.2021.07.006","article-title":"Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS clinical practice guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Gronchi","year":"2021","journal-title":"Annals of Oncology"},{"key":"B6","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1055\/a-2145-8047","article-title":"Neues zu Weichteilsarkomen [Current therapeutic standards in advanced soft tissue sarcomas]","volume":"149","author":"Burkhard-Meier","year":"2024","journal-title":"Deutsche Medizinische Wochenschrift"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1001\/jama.2020.1707","article-title":"Effect of doxorubicin plus olaratumab vs doxorubicin plus placebo on survival in patients with advanced soft tissue sarcomas: the ANNOUNCE randomized clinical trial","volume":"323","author":"Tap","year":"2020","journal-title":"Journal of the American Medical Association"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","article-title":"Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"379","author":"van der Graaf","year":"2012","journal-title":"The Lancet"},{"key":"B9","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/S1470-2045(14)70063-4","article-title":"Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial","volume":"15","author":"Judson","year":"2014","journal-title":"The Lancet Oncology"},{"key":"B10","doi-asserted-by":"publisher","first-page":"3118","DOI":"10.3390\/cancers17193118","article-title":"Reporting matters: severe adverse events in soft tissue sarcoma therapy: a 30-year systematic review of placebo- and non-systemic-controlled randomized trials","volume":"17","author":"Aeschbacher","year":"2025","journal-title":"Cancers"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.3390\/cancers17071203","article-title":"The decline and fall of the current chemotherapy paradigm in soft tissue sarcoma","volume":"17","author":"Rieth","year":"2025","journal-title":"Cancers"},{"key":"B12","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nature Medicine"},{"key":"B13","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s11864-022-00944-6","article-title":"Immunotherapy and biomarkers in sarcoma","volume":"23","author":"Dajsakdipon","year":"2022","journal-title":"Current Treatment Options in Oncology"},{"key":"B14","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s13045-023-01486-6","article-title":"New immunotherapy strategies for patients with sarcomas: highlights from the 2023 ASCO annual meeting","volume":"16","author":"Roulleaux-Dugage","year":"2023","journal-title":"Journal of Hematology & Oncology"},{"key":"B15","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/S1470-2045(23)00282-6","article-title":"Pembrolizumab in patients with rare and ultra-rare sarcomas (AcS\u00e9 Pembrolizumab): analysis of a subgroup from a non-randomised, open-label, phase 2, basket trial","volume":"24","author":"Blay","year":"2023","journal-title":"The Lancet Oncology"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e35628","DOI":"10.1002\/cncr.35628","article-title":"Nivolumab and sunitinib in patients with advanced bone sarcomas: a multicenter, single-arm, phase 2 trial","volume":"131","author":"Palmerini","year":"2025","journal-title":"Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.775761","article-title":"Improving immunotherapy efficacy in soft-tissue sarcomas: a biomarker driven and histotype tailored review","volume":"12","author":"Roulleaux Dugage","year":"2021","journal-title":"Frontiers in Immunology"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.3390\/ijms25021266","article-title":"Role of immunotherapy in sarcomas","volume":"25","author":"Dalal","year":"2024","journal-title":"International Journal of Molecular Sciences"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.3390\/cancers15082287","article-title":"Current landscape of immunotherapy for advanced sarcoma","volume":"15","author":"Albarr\u00e1n","year":"2023","journal-title":"Cancers"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e256697","DOI":"10.1136\/bcr-2023-256697","article-title":"PD-1 inhibition in metastatic high tumour mutational burden (TMB) leiomyosarcoma with clinicopathological correlates","volume":"16","author":"Pandita","year":"2023","journal-title":"BMJ Case Reports"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1038\/s41591-022-01821-3","article-title":"Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohort","volume":"28","author":"Italiano","year":"2022","journal-title":"Nature Medicine"},{"key":"B22","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1002\/iju5.12643","article-title":"A case of adrenal undifferentiated pleomorphic sarcoma with tertiary lymphoid structures responded to pembrolizumab","volume":"6","author":"Kokubun","year":"2023","journal-title":"IJU Case Reports"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e009472","DOI":"10.1136\/jitc-2024-009472","article-title":"A multicenter, randomized, non-comparative, phase II study of nivolumab \u00b1 ipilimumab for patients with metastatic sarcoma (Alliance A091401): expansion cohorts and correlative analyses","volume":"12","author":"Seligson","year":"2024","journal-title":"Journal for Immunotherapy of Cancer"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.3390\/cancers12071873","article-title":"A retrospective analysis of the efficacy of immunotherapy in metastatic soft-tissue sarcomas","volume":"12","author":"Monga","year":"2020","journal-title":"Cancers"},{"key":"B25","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.humpath.2014.11.001","article-title":"Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment","volume":"46","author":"D'Angelo","year":"2015","journal-title":"Human Pathology"},{"key":"B26","doi-asserted-by":"publisher","first-page":"761","DOI":"10.2340\/1651-226X.2025.43135","article-title":"Real-world data on immune checkpoint inhibitors in advanced sarcomas across multiple European institutions","volume":"64","author":"Kokkali","year":"2025","journal-title":"Acta Oncologica"},{"key":"B27","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1159\/000535959","article-title":"Objective responses in metastatic pleomorphic rhabdomyosarcoma treated with combination of doxorubicin and pembrolizumab: a case series","volume":"17","author":"Kournoutas","year":"2024","journal-title":"Case Reports in Oncology"},{"key":"B28","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s12967-021-02829-y","article-title":"Is immunotherapy in the future of therapeutic management of sarcomas","volume":"19","author":"Clemente","year":"2021","journal-title":"Journal of Translational Medicine"},{"key":"B29","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1001\/jamaoncol.2017.1617","article-title":"Use of PD-1 targeting, macrophage infiltration, and IDO pathway activation in sarcomas: a phase 2 clinical trial","volume":"4","author":"Toulmonde","year":"2018","journal-title":"JAMA Oncology"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1001\/jamaoncol.2020.3689","article-title":"Assessment of doxorubicin and pembrolizumab in patients with advanced anthracycline-naive sarcoma: a phase 1\/2 nonrandomized clinical trial","volume":"6","author":"Pollack","year":"2020","journal-title":"JAMA Oncology"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1158\/1078-0432.CCR-21-2258","article-title":"Trabectedin plus durvalumab in patients with advanced pretreated soft tissue sarcoma and ovarian carcinoma (TRAMUNE): an open-label, multicenter phase Ib study","volume":"28","author":"Toulmonde","year":"2022","journal-title":"Clinical Cancer Research"},{"key":"B32","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1097\/CAD.0000000000001088","article-title":"Efficacy and safety of toripalimab combined with doxorubicin as first-line treatment for metastatic soft tissue sarcomas: an observational study","volume":"32","author":"Liu","year":"2021","journal-title":"Anti-Cancer Drugs"},{"key":"B33","doi-asserted-by":"publisher","first-page":"6424","DOI":"10.1158\/1078-0432.CCR-21-2001","article-title":"Phase II study of pembrolizumab in combination with doxorubicin in metastatic and unresectable soft-tissue sarcoma","volume":"27","author":"Livingston","year":"2021","journal-title":"Clinical Cancer Research"},{"key":"B34","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1097\/00000658-198704000-00003","article-title":"Adult soft tissue sarcomas: a pattern of care survey of the American College of Surgeons","volume":"205","author":"Lawrence","year":"1987","journal-title":"Annals of Surgery"},{"key":"B35","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1159\/000509519","article-title":"Prognosis of patients with metastatic soft tissue sarcoma: advances in recent years","volume":"43","author":"Lochner","year":"2020","journal-title":"Oncology Research and Treatment"},{"key":"B36","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1097\/00000658-199905000-00002","article-title":"Pulmonary metastases from soft tissue sarcoma: analysis of patterns of disease and postmetastasis survival","volume":"229","author":"Billingsley","year":"1999","journal-title":"Annals of Surgery"},{"key":"B37","doi-asserted-by":"publisher","first-page":"3898","DOI":"10.1200\/JCO.2016.67.6684","article-title":"PICASSO III: a phase III, placebo-controlled study of doxorubicin with or without palifosfamide in patients with metastatic soft tissue sarcoma","volume":"34","author":"Ryan","year":"2016","journal-title":"Journal of Clinical Oncology"},{"key":"B38","doi-asserted-by":"publisher","first-page":"11015","DOI":"10.1200\/jco.2019.37.15_suppl.11015","article-title":"Clinical activity of pembrolizumab (P) in undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated\/pleomorphic liposarcoma (LPS): final results of SARC028 expansion cohorts","volume":"37","author":"Burgess","year":"2019","journal-title":"Journal of Clinical Oncology"},{"key":"B39","doi-asserted-by":"publisher","first-page":"11009","DOI":"10.1200\/jco.2019.37.15_suppl.11009","article-title":"A phase I\/II study of pembrolizumab (Pem) and doxorubicin (Dox) in treating patients with metastatic\/unresectable sarcoma","volume":"37","author":"Pollack","year":"2019","journal-title":"Journal of Clinical Oncology"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1007\/s11864-022-01036-1","article-title":"Combinations of chemotherapy and PD-1\/PD-L1 inhibitors in sarcoma","volume":"23","author":"Lynch","year":"2022","journal-title":"Current Treatment Options in Oncology"},{"key":"B41","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1016\/S0140-6736(24)01812-9","article-title":"Safety and efficacy of pembrolizumab, radiation therapy, and surgery versus radiation therapy and surgery for stage III soft tissue sarcoma of the extremity (SU2C-SARC032): an open-label, randomised clinical trial","volume":"404","author":"Mowery","year":"2024","journal-title":"The Lancet"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/S1470-2045(17)30624-1","article-title":"Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial","volume":"18","author":"Tawbi","year":"2017","journal-title":"The Lancet Oncology"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1918276\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T05:33:41Z","timestamp":1787808821000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1918276\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,27]]},"references-count":42,"alternative-id":["10.3389\/fimmu.2026.1918276"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1918276","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,27]]},"article-number":"1918276"}}